Just had a quick look at that E&P table in my post above, bit...

First 52 Last

Share
Profile

Follow
TheAnalyst007

14,987 Posts.

3690

31/10/23

22:02

Post #: 70653025
Share

Originally posted by TheAnalyst007: ↑

No worries mate. Look, it is definitely not a blue chip stock that's for sure! However, at a market capitalisation of a little bit above $30m I think you would have trouble finding a similarly valued (or even a higher valued) stock with even half the near-term potential as this one. It is definitely not a sure thing, but from a risk/reward perspective it seems incredibly enticing to me.

We are talking about a company which already has an FDA approved best in class product (not one which is years away from it) generating close to $20m this last financial year, and another incredibly lucrative product currently in the FDA clinical trial stage (and seeking a partner, which is likely to be achieved in the coming months). It is expected (confirmed now thanks to this announcement) that this revenue will continue to grow at a very fast rate for the foreseeable future, likely reaching $30m this coming financial year and that the company will be profitable in the NEAR term. They are loaded up with cash, so based on this near-term profitability assumption, they will never have to raise capital again to fund operations. We also have a very experienced management team who do not pay themselves ridiculously high compensation and clearly are focused on delivering strong returns to shareholders. Yes there are risks, and we should definitely discuss them, but at a $30 million market cap I would expect things not to be perfectly smooth!

Source: E&P Financial

Pictures tell a thousand words, so see below to see recent images capturing the high popularity and high quality of this new procedure and the company more generally. This is only a $30m company apparently...

Expand

Just had a quick look at that E&P table in my post above, bit weird they're using gross margins of only 60% when EYE has an 80% gross margin... guess their model is leaning quite a bit on the conservative side

Last edited by TheAnalyst007: 31/10/23

EYE Price at posting: 18.5¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply